Lilly Loses Its Bloom; Amgen, Regeneron Blossom
October 12, 2015 at 11:06 AM EDT
Bad news for Eli Lilly (LLY) is good news for Amgen (AMGN) and Regeneron (REGN). Lilly announced today it is ending development of its experimental cholesterol drug at the urging of an independent panel because the drug wasn’t effective enough. It seems recommendation is based on data indicating a low probability that the therapy—called evacetrapib—would meet its […]
